Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo
D Reglodi, P Kiss, A Lubics… - Current pharmaceutical …, 2011 - ingentaconnect.com
Pituitary adenylate cyclase activating polypeptide (PACAP) is a pleiotropic and
multifunctional peptide exerting its effects via 3 main receptors (PAC1, VPAC1 and VPAC2) …
multifunctional peptide exerting its effects via 3 main receptors (PAC1, VPAC1 and VPAC2) …
Targeting VIP and PACAP receptor signaling: new insights into designing drugs for the PACAP subfamily of receptors
Pituitary Adenylate Cyclase-Activating Peptide (PACAP) and Vasoactive Intestinal Peptide
(VIP) are neuropeptides involved in a diverse array of physiological and pathological …
(VIP) are neuropeptides involved in a diverse array of physiological and pathological …
Understanding VPAC receptor family peptide binding and selectivity
The vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating
polypeptide (PACAP) receptors are key regulators of neurological processes. Despite recent …
polypeptide (PACAP) receptors are key regulators of neurological processes. Despite recent …
Targeting the PAC1 receptor for neurological and metabolic disorders
C Liao, MP de Molliens, ST Schneebeli… - Current topics in …, 2019 - ingentaconnect.com
The pituitary adenylate cyclase-activating polypeptide (PACAP)-selective PAC1 receptor
(PAC1R, ADCYAP1R1) is a member of the vasoactive intestinal peptide (VIP)/secretin …
(PAC1R, ADCYAP1R1) is a member of the vasoactive intestinal peptide (VIP)/secretin …
Pituitary adenylate cyclase-activating polypeptide (PACAP) has a neuroprotective function in dopamine-based neurodegeneration in rat and snail parkinsonian …
Pituitary adenylate cyclase-activating polypeptide (PACAP) rescues dopaminergic neurons
from neurodegeneration and improves motor changes induced by 6-hydroxy-dopamine (6 …
from neurodegeneration and improves motor changes induced by 6-hydroxy-dopamine (6 …
Cryo-EM structure of the human PAC1 receptor coupled to an engineered heterotrimeric G protein
K Kobayashi, W Shihoya, T Nishizawa… - Nature structural & …, 2020 - nature.com
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a pleiotropic neuropeptide
hormone. The PACAP receptor PAC1R, which belongs to the class B G-protein-coupled …
hormone. The PACAP receptor PAC1R, which belongs to the class B G-protein-coupled …
Probing PAC1 receptor activation across species with an engineered sensor
RB Cola, SN Niethammer, P Rajamannar, A Gresch… - Elife, 2024 - elifesciences.org
Abstract Class-B1 G-protein-coupled receptors (GPCRs) are an important family of clinically
relevant drug targets that remain difficult to investigate via high-throughput screening and in …
relevant drug targets that remain difficult to investigate via high-throughput screening and in …
Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular …
A Lamine, M Létourneau, ND Doan, J Maucotel… - …, 2016 - Elsevier
Parkinson's disease (PD) is characterized by a steady loss of dopamine neurons through
apoptotic, inflammatory and oxidative stress processes. In that line of view, the pituitary …
apoptotic, inflammatory and oxidative stress processes. In that line of view, the pituitary …
A structure–function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists
I Ramos-Álvarez, SA Mantey, T Nakamura… - Peptides, 2015 - Elsevier
Pituitary adenylate cyclase-activating polypeptide (PACAP) has widespread physiological/
pathophysiological actions and there is increased interest for its use therapeutically …
pathophysiological actions and there is increased interest for its use therapeutically …
Generation of KS-133 as a novel bicyclic peptide with a potent and selective VIPR2 antagonist activity that counteracts cognitive decline in a mouse model of …
K Sakamoto, L Chen, T Miyaoka, M Yamada… - Frontiers in …, 2021 - frontiersin.org
Worldwide, more than 20 million people suffer from schizophrenia, but effective and
definitive new therapeutic drugs/treatments have not been established. Vasoactive intestinal …
definitive new therapeutic drugs/treatments have not been established. Vasoactive intestinal …